Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Chronic and recurrent abdominal pain

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Chronic pain can develop an acute complication. New shock, peritonism, persistent obstruction, overt bleeding, fever with immunosuppression, severe dehydration, rapidly worsening focal pain, pregnancy-related collapse or pain with a pulsatile mass requires acute assessment rather than continuation of an outpatient functional pathway.

Synopsis

Classify persistent or episodic abdominal pain by pattern, identify inflammatory, malignant, metabolic and gynaecological warning features, and make a positive, reviewable diagnosis without indiscriminate testing.

  • Describe duration, episodic versus continuous course, exact relation to defecation, meals, posture, movement, menstruation and medicines before attaching a diagnostic label.
  • Weight loss, iron-deficiency anaemia, rectal bleeding, nocturnal symptoms, fever, mass, family cancer history, persistent vomiting and older-age new onset shift the pathway towards prompt investigation.
  • A positive diagnosis of irritable bowel syndrome rests on a compatible symptom pattern, limited exclusion tests and absence of warning features; it is not a synonym for all unexplained pain.
  • Inflammatory markers and faecal calprotectin help discriminate inflammatory bowel disease in suitable adults, but infection, NSAIDs, cancer and age can alter calprotectin and local thresholds vary.
  • Test for coeliac disease while the patient continues eating gluten; starting a gluten-free diet before serology and biopsy planning can make diagnosis unnecessarily difficult.
  • Consider abdominal-wall pain when a small reproducible tender point worsens as the abdominal muscles tense, but do not use that sign to dismiss deeper pathology without context.
  • Endometriosis, ovarian disease, bladder pain, chronic pancreatitis, mesenteric ischaemia, adhesions and neuropathic pain may not be revealed by routine luminal tests.
  • Management should match the dominant mechanism and patient goals: dietetic support, bowel-pattern treatment, activity, sleep, psychological therapy and selected neuromodulation often work as a combined plan.
  • Repeated normal tests are evidence only for the questions they answered. Revisit the diagnosis when the pattern changes instead of repeating the same investigation automatically.

Key red flags

Cancer warning pattern

Unexplained weight loss, iron-deficiency anaemia, rectal bleeding, persistent change in bowel habit, abdominal or rectal mass and relevant age or family history require the current suspected-cancer pathway even when pain is longstanding.

Chronic mesenteric ischaemia

Postprandial pain leading to food avoidance and weight loss in a person with smoking, peripheral vascular disease or other atherosclerotic risk raises intestinal angina. Sudden escalation may indicate acute-on-chronic ischaemia.

Investigation priorities

01
Full blood count and ferritinFirst step

Detect anaemia, iron deficiency, thrombocytosis or other evidence that changes inflammatory and cancer probability.

Management branches

First assessmentPhenotype before testing

Abdominal pain has persisted or recurred over weeks to months.

  1. Build a symptom timeline linked to stool, meals, movement, menstruation and medicines, and document weight, nutrition and functional impact.
  2. Actively seek bleeding, anaemia symptoms, nocturnal disturbance, fever, vomiting, mass, family history and a recent qualitative change from baseline.
  3. Examine for pallor, nutrition, nodes, masses, organomegaly, hernias and focal wall tenderness, adding rectal or pelvic assessment only for a defined indication.
  4. Agree a leading phenotype and dangerous alternatives, then select limited tests that will alter referral or treatment rather than ordering an indiscriminate panel.

Key medicines

Antispasmodic for IBS-type painUse a time-limited trial at the current BNF dose chosen for the individual preparation, then continue only if a meaningful benefit is demonstrated.Anticholinergic effects can worsen constipation, urinary retention, glaucoma or cognitive impairment. Stop ineffective treatment and do not use symptomatic improvement to dismiss newly emerging warning features.
Low-dose tricyclic neuromodulatorStart below antidepressant dosing at night and titrate slowly under the current NICE and BNF approach, reviewing benefit and adverse effects regularly.Check overdose risk, cardiac history, sedation, anticholinergic burden and constipation. Explain the analgesic purpose, avoid abrupt escalation and use specialist advice when uncertainty or comorbidity is substantial.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG61 irritable bowel syndromePositive diagnosis, limited exclusion testing, diet, medicines and review for adult IBS.
  • BSG irritable bowel syndrome guidelineUK specialist framework for diagnosis and layered management of IBS.
  • NICE NG20 coeliac diseaseWho to test, gluten exposure, serology and specialist diagnostic confirmation.
  • NICE DG11 faecal calprotectinUse of faecal calprotectin to distinguish inflammatory from non-inflammatory bowel disease.
  • NICE NG12 suspected cancerCurrent FIT, warning-feature and referral pathways for gastrointestinal malignancy.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom